Shin Nippon Biomedical Laboratories
在场
是其中之一......
Shin Nippon Biomedical Laboratories 是一家在股票代码 2395 (JP) 下上市的公司。
涉及Shin Nippon Biomedical Laboratories的并购和融资。
- Shin Nippon Biomedical Laboratories has announced the acquisition of Satsuma Pharmaceuticals (公布2023四月18号).
高管
查看带有其 27 名主要高管的组织结构图
Shin Nippon Biomedical Laboratories 搜索最多的简介
- Ryoichi Nagata, Chairman of the Board, Chief Executive Officer, Ch...
- Takashi Yamashita, Non-Executive Independent Director
- Shinichi Fukumoto, Non-Executive Independent Director
创建提醒
跟踪 Shin Nippon Biomedical Laboratories 的高管变动
生物技术
Shin Nippon Biomedical Laboratories 拥有 2,317 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- AgomAb Therapeutics 刚刚宣布为 89 筹款数百万美元。 (公布2024十月29号).
- Seaport Therapeutics 刚刚宣布为 225 筹款数百万美元。 (公布2024十月25号).
- TuHura Biosciences and Kintara Therapeutics have merged (公布2024十月20号)..
生物技术 行业的其他推荐联系人
消息
Shin Nippon Biomedical Laboratories 的最新新闻稿
- Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - Wave Life Sciences
- Wave Life Sciences Announces Initiation of Dosing in RestorAATion Clinical Program Evaluating First-Ever RNA Editing Candidate, WVE-006, for Alpha-1 Antitrypsin Deficiency - Wave Life Sciences
- Wave Life Sciences Announces Positive Results from Phase 1b/2a SELECT-HD Trial with First Clinical Demonstration of Allele-Selective Mutant Huntingtin Lowering in Huntington’s Disease - Wave Life Sciences
- Wave Life Sciences Announces Positive Interim Data from FORWARD-53 Clinical Trial Evaluating WVE-N531 in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping - Wave Life Sciences
- Wave Life Sciences Prices $100 Million Public Offering of Ordinary Shares - Wave Life Sciences
- We released materials for presentation on nasal administration basic technology briefing session - SNBL
- View more press releases Close
通过电子邮件
